Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765250 in Moderate to Severe Plaque Psoriasis
NCT05728489Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of BI 765250 in plaque psoriasis (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any adverse events. Started Apr 2023; status: completed.
02
Drugs
BI 765250
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05728489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728489.